Elon Musk’s Neuralink to Test Brain Chips in Clinical Study in Great Britain

2024 02 20T083311Z 2 LYNXNPEK1J07R RTROPTP 4 NEURALINK HUMANTRIALS 1 1708426830999



2024 02 20T083311Z 2 LYNXNPEK1J07R RTROPTP 4 NEURALINK HUMANTRIALS 1 1708426830999

Elon Musk’s brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts.

The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X.

Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study.

The company raised $650 million (roughly Rs. 5,676 crore) in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the US Food and Drug Administration, which had initially rejected Neuralink’s application in 2022.

According to the company, five patients with severe paralysis are currently using its…



Source link

Disclaimer


We strive to uphold the highest ethical standards in all of our reporting and coverage. We 5guruayurveda.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on. For any glitch kindly connect at 5guruayurveda.com

Leave a Reply

Your email address will not be published. Required fields are marked *